Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29176357 | 1.00 | MLLT1 (0.60) | MLLT1DRD4NPC1RAB9ASMYD3 | |
| SCHEMBL29176327 | 0.99 | MLLT1 (0.61) | MLLT1DRD4NPC1RAB9ASMYD3 | |
| SCHEMBL20535296 | 0.96 | MLLT1 (0.57) | MLLT1DRD4NPC1RAB9ASMYD3 | |
| SCHEMBL20534668 | 0.93 | DRD4 (0.58) | MLLT1DRD4RAB9ASMYD3HRH4 | |
| SCHEMBL3612493 | 0.87 | DRD4 (0.50) | MLLT1DRD4HRH4 | |
| SCHEMBL3612490 | 0.87 | DRD4 (0.50) | MLLT1DRD4HRH4 | |
| SCHEMBL17209754 | 0.84 | MLLT1 (0.60) | MLLT1NPC1RAB9ASMYD3PLA2G7 | |
| SCHEMBL3599033 | 0.84 | DRD4 (0.52) | MLLT1DRD4SMYD3HRH4 | |
| SCHEMBL3599027 | 0.84 | DRD4 (0.52) | MLLT1DRD4SMYD3HRH4 | |
| SCHEMBL3599029 | 0.84 | DRD4 (0.52) | MLLT1DRD4SMYD3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | UNIV JOHNS HOPKINS (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | UNIV JOHNS HOPKINS (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2016171743-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | IDO2, IDO1, INMT | MLLT1 399/4885DRD4 1248/4885NPC1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.